Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Horowitz

Showing results (141-150 of 219) with videos related to

Pageof 22
Sort By:
Orphanet Journal of Rare Diseases|October 18, 2013
Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trialHiroshi Kitoh, Masataka Achiwa, Hiroshi Kaneko, et al.
Journal of Geriatric Cardiology : JGC|April 23, 2016
Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillationNathan Ek Procter, Jocasta Ball, Doan Tm Ngo, et al.
British Journal of Clinical Pharmacology|October 15, 2013
Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptakeNigel E Drury, Giovanni Licari, Cher-Rin Chong, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2003
Survival after myocardial revascularization for ischemic cardiomyopathy: a prospective ten-year follow-up studyPallav J Shah, David L Hare, Jai S Raman, et al.
The American Journal of Medicine|May 22, 2013
Premature aging of cardiovascular/platelet function in polycystic ovarian syndromeWai Ping A Chan, Doan T Ngo, Aaron L Sverdlov, et al.
European Heart Journal|July 10, 2012
Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeuticsAaron L Sverdlov, Doan T M Ngo, Wai P A Chan, et al.
Journal of the American College of Cardiology|June 12, 2012
Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patientsScott R Willoughby, Sharmalar Rajendran, Wai P Chan, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineBenjamin J L Davies, Janet K Coller, Heather M James, et al.
Herz|July 3, 2015
Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieuNathan E K Procter, Jocasta Ball, Doan T M Ngo, et al.
Plos One|November 13, 2012
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophyJennifer C Irvine, Virat Ganthavee, Jane E Love, et al.
Pageof 22

Showing results (141-150 of 219) with videos related to

Sort By:
Pageof 22
Orphanet Journal of Rare Diseases|October 18, 2013
Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trialHiroshi Kitoh, Masataka Achiwa, Hiroshi Kaneko, et al.
Journal of Geriatric Cardiology : JGC|April 23, 2016
Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillationNathan Ek Procter, Jocasta Ball, Doan Tm Ngo, et al.
British Journal of Clinical Pharmacology|October 15, 2013
Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptakeNigel E Drury, Giovanni Licari, Cher-Rin Chong, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2003
Survival after myocardial revascularization for ischemic cardiomyopathy: a prospective ten-year follow-up studyPallav J Shah, David L Hare, Jai S Raman, et al.
The American Journal of Medicine|May 22, 2013
Premature aging of cardiovascular/platelet function in polycystic ovarian syndromeWai Ping A Chan, Doan T Ngo, Aaron L Sverdlov, et al.
European Heart Journal|July 10, 2012
Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeuticsAaron L Sverdlov, Doan T M Ngo, Wai P A Chan, et al.
Journal of the American College of Cardiology|June 12, 2012
Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patientsScott R Willoughby, Sharmalar Rajendran, Wai P Chan, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineBenjamin J L Davies, Janet K Coller, Heather M James, et al.
Herz|July 3, 2015
Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieuNathan E K Procter, Jocasta Ball, Doan T M Ngo, et al.
Plos One|November 13, 2012
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophyJennifer C Irvine, Virat Ganthavee, Jane E Love, et al.
Pageof 22